Over the past decade, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged as a transformative class of pharmacotherapies for obesity and type 2 diabetes mellitus (T2D) [1,2]. The gene discussed is GCG; the disease is type 2 diabetes mellitus.